
Organon (NYSE:OGN) reported third-quarter adjusted earnings of $1.01 per share on Monday, beating the consensus estimate of 94 cents. The global healthcare company reported quarterly sales of $1.602 billion, beating the Wall Street estimate of $1.56 billion.
Sales increased 1% on an as-reported basis and down 1% excluding the impact of foreign currency (ex-FX).